Form 4: Vanda Pharmaceuticals CEO Reports Stock Transactions

Mihael Hristos Polymeropoulos, CEO of Vanda Pharmaceuticals, reports disposition of shares to cover tax obligations and acquisition of shares through open market purchases.

Summary

• On March 1, 2025, Mihael Hristos Polymeropoulos, the President and CEO and Chairman of the Board of Vanda Pharmaceuticals, disposed of 95,999 shares of common stock to cover tax withholding obligations at a price of $4.76 per share.
• On March 3, 2025, Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals' common stock at a weighted average price of $4.705 per share, with individual transactions ranging from $4.69 to $4.72.
• Following these transactions, Polymeropoulos directly owns 2,275,731 shares of Vanda Pharmaceuticals.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions involve both disposal for tax obligations and acquisition of shares, balancing out the potential positive and negative signals.

Positives

• The CEO's purchase of 10,000 shares could be interpreted as a sign of confidence in the company's future prospects.

Negatives

• The disposal of 95,999 shares, even for tax obligations, could be viewed negatively by some investors.

Risks

• The stock transactions by the CEO could lead to short-term price volatility.
• Investor sentiment may be affected by the CEO's stock activity.

Industry Context

Insider trading activity is always closely watched by investors as it can provide signals about the management's view of the company's prospects. It is common for executives to sell shares to cover tax obligations related to vesting of stock awards.

Stakeholder Impact

• Shareholders may react to the reported stock transactions by the CEO.
• The transactions could influence investor confidence in the company.

Key Dates